{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-046296","form_type":"8-K","ticker":null,"cik":"0001426332","company_name":"NGM BIOPHARMACEUTICALS INC","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.153826+00:00","generated_at":"2026-06-05T14:57:17.696039+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NGM Biopharmaceuticals to be acquired by Column Group affiliates for $1.55/share (80% premium), going private","bullets":["Acquisition price $1.55/share in cash, an 80% premium to Dec 29, 2023 closing price before TCG's expression of interest.","Total equity value ~$135M on fully diluted basis; NGM had ~$166M cash/securities as of Sep 30, 2023, ~$144.2M as of Dec 31.","Special Committee of independent directors unanimously recommends deal; TCG (26% holder) and rollover stockholders contribute shares instead of cash.","Tender offer requires majority of unaffiliated shares tendered; no financing condition; expected close Q2 2024; NGM to become private."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-046296","json":"https://secwatch.observer/filing/0001193125-24-046296.json","markdown":"https://secwatch.observer/filing/0001193125-24-046296.md","text":"https://secwatch.observer/filing/0001193125-24-046296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426332/000119312524046296/0001193125-24-046296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426332/000119312524046296/d796872d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T14:57:17.696039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99376699c1e195f6f3eded8bbe0bc56a08e70ef9","claim":"NGM BIOPHARMACEUTICALS INC entered into Agreement and Plan of Merger with Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc. (effective 2024-02-25).","evidence_excerpt":"On February 25, 2024, NGM Biopharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Atlas Neon Parent, Inc., a Delaware corporation (“Parent”), and Atlas Neon Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426332/000119312524046296/0001193125-24-046296-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc."},{"label":"Effective","value":"2024-02-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}